-

Shareholder Alert: The Ademi Firm Investigates Whether First IC Corporation Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating First IC (OTCEM: FIEB) for possible breaches of fiduciary duty and other violations of law in its transaction with MetroCity.

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.

Based on the closing price of MetroCity common stock of $27.78 per share on March 14, 2025, the implied purchase price is $22.71 per First IC common share, with consideration consisting of approximately 46% stock and 54% cash and an aggregate transaction value of approximately $206 million. First IC insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for First IC by imposing a significant penalty if First IC accepts a competing bid. We are investigating the conduct of the First IC board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi & Fruchter LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

Ademi & Fruchter LLP


Release Versions

Contacts

Ademi & Fruchter LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

More News From Ademi & Fruchter LLP

Shareholder Alert: The Ademi Firm Investigates Whether 89bio, Inc. is Obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating 89bio (Nasdaq: ETNB) for possible breaches of fiduciary duty and other violations of law in its transaction with Roche. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of 89bio will receive $14.50 per share in cash at closing, plus a non-tradeable CVR to receive certain milestone payme...

Shareholder Alert: The Ademi Firm Investigates Whether Paramount Group Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Paramount (NYSE: PGRE) for possible breaches of fiduciary duty and other violations of law in its transaction with a Rithm Capital. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of Paramount will receive $6.60 per fully diluted share in an all-cash transaction valued at approximately...

Shareholder Alert: The Ademi Firm Continues to Investigate Whether TEGNA Inc. is Obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating TEGNA (NYSE: TEGNA) for possible breaches of fiduciary duty and other violations of law in its going-private transaction. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of TEGNA will receive $22.00 per share in an all-cash transaction valued at $6.2 billion, including TEGNA's net debt...
Back to Newsroom